Spectrum Brands Posts Mixed Q2 Earnings As Gross Profit Decrease 4.5% To $263.5M

Spectrum Brands Holdings Inc (NYSE: SPB) reported a second-quarter (Q2) 2023 sales decline of 10.1% year-on-year to $735.5 million, missing the analyst consensus estimate of $780.9

Spectrum Brands Holdings Inc (NYSE:SPB) reported a second-quarter (Q2) 2023 sales decline of 10.1% year-on-year to $735.5 million, missing the analyst consensus estimate of $780.97 million.

Net sales declined due to retailer inventory management strategies and slower than expected category POS, offset by positive pricing adjustments.

Net sales from Home & Personal Care decreased 16%, Global Pet Care fell 6.2%, and Home & Garden dropped 6%.

Gross profit decreased 4.5% Y/Y to $263.5 million, and the margin contracted 210 basis points to 35.8%.

The operating expenses rose 63.5% Y/Y to $388.2 million. The operating loss for the quarter was $124.7 million versus an income of $3.7 million last year.

The company held $2.9 billion in cash and equivalents as of July 2.

Adjusted EBITDA increased 23%, and the margin expanded 360 basis points attributable to lower distribution costs, fixed cost reduction initiatives and positive pricing impact, partially offset by the reduction in sales volume.

Adjusted EPS of $0.75 beat the analyst consensus estimate of $0.57.

“While we are disappointed with our top-line performance in the quarter, I am pleased with the fact that our focus on profitability is paying off as we exceeded third quarter EBITDA expectations, excluding investment income,” Spectrum chairman and CEO David Maura said.

Outlook: Spectrum Brands reiterated FY23 sales outlook of mid-single digit decline with foreign exchange expected to have a negative impact based upon current rates.

It expects 2023 adjusted EBITDA to decline by low to mid single-digits.

Price Action: SPB shares closed lower by 0.27% at $75.11 on Thursday.

Now Read: Bristol-Myers Squibb, Toast And A Major REIT Stock – CNBC’s ‘Final Trades’
Total
0
Shares
Related Posts
Read More

Medical Cannabis Pioneer cbdMD Secures $1.2M To Fund Rollout Of Functional Mushroom Products

Medical cannabis producer cbdMD has secured $1.25m in financing from five institutional investors to support the national rollout of its new ATRx Labs functional mushroom products. North Carolina-based cbdMD will use the proceeds for working capital as well. The news comes after the company launched two new products--Apple Cider Vinegar (ACV) and Immunity Gummy Pouches-through grocery chain Sprouts Farmers Market. Sprouts chose cbdMD to be a leading brand in its CBD section. The institutional investors will receive a senior secured original issue discount convertible promissory note, which matures 18 months from the date of issue. At that point, the notes can be converted into shares at a rate of $0.684 per share.

YCBD